A 66-year-old male was prescribed phenelzine (Nardil) while in an acute psychiatric unit for recalcitrant depression. The nurse practitioner (NP) managing his primary health care needs to understand the following regarding phenelzine and other monoamine oxidase inhibitors (MAOIs):

Medroxyprogesterone (Depo-Provera) is a long-acting injectable contraceptive that suppresses ovulation by inhibiting the hypothalamic-pituitary-ovarian axis. It is highly effective and convenient because it requires administration only every three months. However, its prolonged use has been associated with significant effects on bone metabolism, especially in adolescents and young adults. This risk is highlighted in its boxed warning and requires patient counseling and monitoring.

Rationale:
A. Increased risk of strokes is more commonly associated with estrogen-containing contraceptives rather than progestin-only methods like Medroxyprogesterone (Depo-Provera). While any hormonal therapy may carry some vascular risk depending on patient factors, stroke risk is not the primary boxed warning for this medication.

B. Decreased bone mineral density is the black box warning associated with Medroxyprogesterone (Depo-Provera). Prolonged use suppresses estrogen levels, which can lead to reduced bone formation and increased bone resorption. This effect is particularly concerning in adolescents and young adults, and long-term use requires careful risk-benefit assessment and counseling on bone health.

C. Stevens-Johnson syndrome is not associated with Medroxyprogesterone (Depo-Provera). Severe cutaneous hypersensitivity reactions are not a known boxed warning for this medication. SJS is more commonly associated with certain anticonvulsants and antibiotics rather than hormonal contraceptives.

D. Significant hypertension is not a recognized black box warning or primary adverse effect of Medroxyprogesterone (Depo-Provera). Unlike estrogen-containing contraceptives, progestin-only injections have a lower impact on blood pressure regulation. While monitoring is still important in hypertensive patients, it is not the primary boxed warning concern.

Diaper dermatitis is an inflammatory skin condition in infants caused by prolonged exposure to moisture, friction, urine, and feces, often complicated by irritant or mild inflammatory processes. Treatment focuses on reducing inflammation, protecting the skin barrier, and minimizing exposure to irritants. Topical corticosteroids may be used cautiously when inflammation is present, but potency and safety are critical considerations due to the increased absorption in diaper-covered skin.

Rationale:
A. High-potency corticosteroids such as Betamethasone dipropionate 0.05% are not appropriate for diaper dermatitis because infant skin, especially in the diaper area, has increased absorption leading to a higher risk of systemic steroid effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression and skin atrophy. These agents are reserved for severe inflammatory dermatologic conditions, not routine diaper rash.

B. Low-potency corticosteroids such as Hydrocortisone 1% are the safest option when a corticosteroid is needed for diaper dermatitis. They effectively reduce mild inflammation while minimizing the risk of systemic absorption and local adverse effects. Short-term use is recommended, along with barrier protection and frequent diaper changes.

C. Corticosteroids are not absolutely contraindicated in diaper dermatitis; low-potency agents may be used briefly when significant inflammation is present. Avoiding them entirely is not necessary in all cases. However, they should be used cautiously and not as first-line monotherapy without barrier care.

D. Intermediate potency corticosteroids such as Triamcinolone 0.1% are too strong for routine use in diaper dermatitis. The occlusive nature of the diaper area increases absorption, raising the risk of systemic side effects and skin damage. These agents are generally reserved for more severe inflammatory skin disorders in less sensitive areas.